111 related articles for article (PubMed ID: 32239932)
1. Insights into PPARγ Phosphorylation and Its Inhibition Mechanism.
Montanari R; Capelli D; Yamamoto K; Awaishima H; Nishikata K; Barendregt A; Heck AJR; Loiodice F; Altieri F; Paiardini A; Grottesi A; Pirone L; Pedone E; Peiretti F; Brunel JM; Itoh T; Pochetti G
J Med Chem; 2020 May; 63(9):4811-4823. PubMed ID: 32239932
[TBL] [Abstract][Full Text] [Related]
2. Exploring the mechanism of PPARγ phosphorylation mediated by CDK5.
Ribeiro Filho HV; Guerra JV; Cagliari R; Batista FAH; Le Maire A; Oliveira PSL; Figueira ACM
J Struct Biol; 2019 Sep; 207(3):317-326. PubMed ID: 31319193
[TBL] [Abstract][Full Text] [Related]
3. Molecular Recognition of PPARγ by Kinase Cdk5/p25: Insights from a Combination of Protein-Protein Docking and Adaptive Biasing Force Simulations.
Mottin M; Souza PC; Skaf MS
J Phys Chem B; 2015 Jul; 119(26):8330-9. PubMed ID: 26047365
[TBL] [Abstract][Full Text] [Related]
4. A novel non-agonist peroxisome proliferator-activated receptor γ (PPARγ) ligand UHC1 blocks PPARγ phosphorylation by cyclin-dependent kinase 5 (CDK5) and improves insulin sensitivity.
Choi SS; Kim ES; Koh M; Lee SJ; Lim D; Yang YR; Jang HJ; Seo KA; Min SH; Lee IH; Park SB; Suh PG; Choi JH
J Biol Chem; 2014 Sep; 289(38):26618-26629. PubMed ID: 25100724
[TBL] [Abstract][Full Text] [Related]
5. Antidiabetic actions of a non-agonist PPARγ ligand blocking Cdk5-mediated phosphorylation.
Choi JH; Banks AS; Kamenecka TM; Busby SA; Chalmers MJ; Kumar N; Kuruvilla DS; Shin Y; He Y; Bruning JB; Marciano DP; Cameron MD; Laznik D; Jurczak MJ; Schürer SC; Vidović D; Shulman GI; Spiegelman BM; Griffin PR
Nature; 2011 Sep; 477(7365):477-81. PubMed ID: 21892191
[TBL] [Abstract][Full Text] [Related]
6. Structural basis for the inhibitory effects of a novel reversible covalent ligand on PPARγ phosphorylation.
Jang JY; Kim H; Kim HJ; Suh SW; Park SB; Han BW
Sci Rep; 2019 Aug; 9(1):11168. PubMed ID: 31371757
[TBL] [Abstract][Full Text] [Related]
7. Anti-diabetic drugs inhibit obesity-linked phosphorylation of PPARgamma by Cdk5.
Choi JH; Banks AS; Estall JL; Kajimura S; Boström P; Laznik D; Ruas JL; Chalmers MJ; Kamenecka TM; Blüher M; Griffin PR; Spiegelman BM
Nature; 2010 Jul; 466(7305):451-6. PubMed ID: 20651683
[TBL] [Abstract][Full Text] [Related]
8. Development of an ELISA for High-Throughput Screening of Inhibitors of Cdk5-Mediated PPARγ Phosphorylation.
Prokoph N; Ormö M; O'Mahony G; Hogner A; McPheat J; Karlsson U; Holmberg Schiavone L; Liu J
Assay Drug Dev Technol; 2016 May; 14(4):261-72. PubMed ID: 27027223
[TBL] [Abstract][Full Text] [Related]
9. Biological Screening and Crystallographic Studies of Hydroxy γ-Lactone Derivatives to Investigate PPARγ Phosphorylation Inhibition.
Capelli D; Cazzaniga G; Mori M; Laghezza A; Loiodice F; Quaglia M; Negro E; Meneghetti F; Villa S; Montanari R
Biomolecules; 2023 Apr; 13(4):. PubMed ID: 37189440
[TBL] [Abstract][Full Text] [Related]
10. Structural Basis for the Regulation of PPARγ Activity by Imatinib.
Jang JY; Kim HJ; Han BW
Molecules; 2019 Oct; 24(19):. PubMed ID: 31581474
[TBL] [Abstract][Full Text] [Related]
11. Identification of the First PPARα/γ Dual Agonist Able To Bind to Canonical and Alternative Sites of PPARγ and To Inhibit Its Cdk5-Mediated Phosphorylation.
Laghezza A; Piemontese L; Cerchia C; Montanari R; Capelli D; Giudici M; Crestani M; Tortorella P; Peiretti F; Pochetti G; Lavecchia A; Loiodice F
J Med Chem; 2018 Sep; 61(18):8282-8298. PubMed ID: 30199253
[TBL] [Abstract][Full Text] [Related]
12. An ERK/Cdk5 axis controls the diabetogenic actions of PPARγ.
Banks AS; McAllister FE; Camporez JP; Zushin PJ; Jurczak MJ; Laznik-Bogoslavski D; Shulman GI; Gygi SP; Spiegelman BM
Nature; 2015 Jan; 517(7534):391-5. PubMed ID: 25409143
[TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of PPARγ Affects the Collective Motions of the PPARγ-RXRα-DNA Complex.
Lemkul JA; Lewis SN; Bassaganya-Riera J; Bevan DR
PLoS One; 2015; 10(5):e0123984. PubMed ID: 25954810
[TBL] [Abstract][Full Text] [Related]
14. L312, a novel PPARγ ligand with potent anti-diabetic activity by selective regulation.
Xie X; Zhou X; Chen W; Long L; Li W; Yang X; Li S; Wang L
Biochim Biophys Acta; 2015 Jan; 1850(1):62-72. PubMed ID: 25305559
[TBL] [Abstract][Full Text] [Related]
15. A computational study to identify the key residues of peroxisome proliferator-activated receptor gamma in the interactions with its antagonists.
Sharifi T; Ghayeb Y
J Biomol Struct Dyn; 2018 May; 36(7):1822-1833. PubMed ID: 28566016
[TBL] [Abstract][Full Text] [Related]
16. Homology modeling and molecular docking studies on Type II diabetes complications reduced PPARγ receptor with various ligand molecules.
Prabhu S; Vijayakumar S; Manogar P; Maniam GP; Govindan N
Biomed Pharmacother; 2017 Aug; 92():528-535. PubMed ID: 28575810
[TBL] [Abstract][Full Text] [Related]
17. Selective targeting of PPARγ by the natural product chelerythrine with a unique binding mode and improved antidiabetic potency.
Zheng W; Qiu L; Wang R; Feng X; Han Y; Zhu Y; Chen D; Liu Y; Jin L; Li Y
Sci Rep; 2015 Jul; 5():12222. PubMed ID: 26183621
[TBL] [Abstract][Full Text] [Related]
18. PPARγ S273 Phosphorylation Modifies the Dynamics of Coregulator Proteins Recruitment.
Dias MMG; Batista FAH; Tittanegro TH; de Oliveira AG; Le Maire A; Torres FR; Filho HVR; Silveira LR; Figueira ACM
Front Endocrinol (Lausanne); 2020; 11():561256. PubMed ID: 33329381
[TBL] [Abstract][Full Text] [Related]
19. PPARγ non-covalent antagonists exhibit mutable binding modes with a similar free energy of binding: a case study.
Fratev F
J Biomol Struct Dyn; 2017 Feb; 35(3):476-485. PubMed ID: 26872742
[TBL] [Abstract][Full Text] [Related]
20. Peroxisome Proliferator-Activated Receptor γ (PPARγ) and Ligand Choreography: Newcomers Take the Stage.
Garcia-Vallvé S; Guasch L; Tomas-Hernández S; del Bas JM; Ollendorff V; Arola L; Pujadas G; Mulero M
J Med Chem; 2015 Jul; 58(14):5381-94. PubMed ID: 25734377
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
